ARTICLE | Company News

Teva, UCB, Nycomed, Pfizer, Sun Pharmaceutical gastrointestinal news

July 26, 2010 7:00 AM UTC

A judge in the U.S. District Court for the District of New Jersey confirmed an April jury verdict that upheld the validity of Nycomed's patent covering gastrointestinal drug Protonix pantoprazole. The jury found that U.S. Patent No. 4,758,579 was infringed by generic versions of Protonix launched by Teva in 2007 and by Sun in 2008. The patent, which expires in January 2011, is owned by Nycomed and licensed to Wyeth, now part of Pfizer. Nycomed said it will pursue damage claims in this case. Nycomed said that Protonix sales reached $1.9 billion in 2007, but had since decreased "considerably." ...